Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Oct 23

PMID 39443013

Authors

John G F Cleland

Pierpaolo Pellicori

Fraser J Graham

Rebecca Lane

Mark C Petrie

Fozia Ahmed

Iain B Squire

Andrew Ludman

Alan Japp

Abdallah Al-Mohammad

Andrew L Clark

Ben Szwejkowski

Chris Critoph

Victor Chong

Rebekah Schiff

Thuraia Nageh

Jason Glover

John J V McMurray

Elizabeth A Thomson

Michele Robertson

Ian Ford

Philip A Kalra

Paul R Kalra

Affiliations

Soon will be listed here.

Abstract

Background: Patients with heart failure and iron deficiency have diverse causes for hospitalization and death that might be affected by iron repletion.

Objectives: The purpose of this study was to explore causes of hospitalizations and deaths in a randomized trial (IRONMAN) of heart failure comparing intravenous ferric derisomaltose (FDI) (n = 568) and usual care (n = 569).

Methods: Patients with heart failure, left ventricular ejection fraction ≤45%, and either transferrin saturation <20% or serum ferritin <100 μg/L were enrolled. Median follow-up was 2.7 years (Q1-Q3: 1.8-3.6 years). A committee adjudicated the main and contributory causes of unplanned hospitalizations and deaths. RRs (rate ratios) for selected recurrent events with 95% CIs are also reported.

Results: Compared with usual care, patients randomized to FDI had fewer unplanned hospitalizations (RR: 0.83; 95% CI: 0.71-0.97; P = 0.02), with similar reductions in cardiovascular (RR: 0.83; 95% CI: 0.69-1.01) and noncardiovascular (RR: 0.83; 95% CI: 0.67-1.03) hospitalizations, as well as hospitalizations for heart failure (RR: 0.78; 95% CI: 0.60-1.00), respiratory disease (RR: 0.70; 95% CI: 0.53-0.97), or infection (RR: 0.82; 95% CI: 0.66-1.03). Heart failure was the main cause for 26% of hospitalizations and contributed to or complicated a further 12%. Infection caused or contributed to 38% of all hospitalizations, including 27% of heart failure hospitalizations. Patterns of cardiovascular and all-cause mortality were similar for patients assigned to FDI or usual care.

Conclusions: In IRONMAN, FDI exerted similar reductions in cardiovascular and noncardiovascular hospitalizations, suggesting that correcting iron deficiency might increase resistance or resilience to a broad range of problems that cause hospitalizations in patients with heart failure. (Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency; NCT02642562).

References

Cleland J, Massie B, Packer M . Sudden death in heart failure: vascular or electrical?. Eur J Heart Fail. 2000; 1(1):41-5. DOI: 10.1016/S1388-9842(99)00009-4. View

Kalra P, Cleland J, Petrie M, Ahmed F, Foley P, Kalra P . Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart. 2022; 108(24):1979-1985. PMC: 9726969. DOI: 10.1136/heartjnl-2022-321304. View

Shoaib A, Van Spall H, Wu J, Cleland J, McDonagh T, Rashid M . Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. Eur Heart J Qual Care Clin Outcomes. 2021; 7(4):378-387. PMC: 8244536. DOI: 10.1093/ehjqcco/qcab040. View

Hicks K, Mahaffey K, Mehran R, Nissen S, Wiviott S, Dunn B . 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018; 71(9):1021-1034. DOI: 10.1016/j.jacc.2017.12.048. View

Elstrott B, Lakshmanan H, Melrose A, Jordan K, Martens K, Yang C . Platelet reactivity and platelet count in women with iron deficiency treated with intravenous iron. Res Pract Thromb Haemost. 2022; 6(2):e12692. PMC: 8941679. DOI: 10.1002/rth2.12692. View

Abraham W, Psotka M, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R . Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC Heart Fail. 2020; 8(12):961-972. DOI: 10.1016/j.jchf.2020.10.002. View

Shen L, Jhund P, Anand I, Bhatt A, Desai A, Maggioni A . Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021; 77(16):1961-1973. DOI: 10.1016/j.jacc.2021.03.001. View

Savarese G, von Haehling S, Butler J, Cleland J, Ponikowski P, Anker S . Iron deficiency and cardiovascular disease. Eur Heart J. 2022; 44(1):14-27. PMC: 9805408. DOI: 10.1093/eurheartj/ehac569. View

Martin-Ontiyuelo C, Rodo-Pin A, Echeverria-Esnal D, Admetllo M, Duran-Jorda X, Alvarado M . Intravenous Iron Replacement Improves Exercise Tolerance in COPD: A Single-Blind Randomized Trial. Arch Bronconeumol. 2022; 58(10):689-698. DOI: 10.1016/j.arbres.2021.08.011. View

10.

Anker M, Hulsmann M, Cleland J . What do patients with heart failure die from? A single assassin or a conspiracy?. Eur J Heart Fail. 2019; 22(1):26-28. DOI: 10.1002/ejhf.1689. View

11.

Preston A, Drakesmith H, Frost J . Adaptive immunity and vaccination - iron in the spotlight. Immunother Adv. 2022; 1(1):ltab007. PMC: 9327113. DOI: 10.1093/immadv/ltab007. View

12.

Lakhal-Littleton S, Cleland J . Iron deficiency and supplementation in heart failure. Nat Rev Cardiol. 2024; 21(7):463-486. DOI: 10.1038/s41569-024-00988-1. View

13.

Cleland J, Kalra P, Pellicori P, Graham F, Foley P, Squire I . Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. Eur Heart J. 2024; 45(16):1410-1426. PMC: 11032711. DOI: 10.1093/eurheartj/ehae086. View

14.

Shen L, Jhund P, Petrie M, Claggett B, Barlera S, Cleland J . Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017; 377(1):41-51. DOI: 10.1056/NEJMoa1609758. View

15.

Liu Y, Clarke R, Bennett D, Zong G, Gan W . Iron Status and Risk of Heart Disease, Stroke, and Diabetes: A Mendelian Randomization Study in European Adults. J Am Heart Assoc. 2024; 13(6):e031732. PMC: 11010009. DOI: 10.1161/JAHA.123.031732. View

16.

Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V . Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2011; 5(1):54-62. DOI: 10.1161/CIRCHEARTFAILURE.111.963413. View

17.

Carson P, Teerlink J, Komajda M, Anand I, Anker S, Butler J . Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. JACC Heart Fail. 2023; 11(4):407-417. DOI: 10.1016/j.jchf.2022.11.017. View

18.

Gillum R, Sempos C, Makuc D, Looker A, Chien C, Ingram D . Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic Followup Study. National Health and Nutrition Examination Survey. Am J Epidemiol. 1996; 144(1):59-68. DOI: 10.1093/oxfordjournals.aje.a008855. View

19.

Macdougall I, White C, Anker S, Bhandari S, Farrington K, Kalra P . Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med. 2018; 380(5):447-458. DOI: 10.1056/NEJMoa1810742. View

20.

Santer P, McGahey A, Frise M, Petousi N, Talbot N, Baskerville R . Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial. BMJ Open Respir Res. 2020; 7(1). PMC: 7311010. DOI: 10.1136/bmjresp-2020-000577. View